Photodynamic Therapy

Photodynamic therapy involves administration of a tumorlocalizing photosensitizing agent, which may require metabolic synthesis (i.e., a prodrug), followed by activation of the agent by light of a specific wavelength. This therapy results in a sequence of photochemical and photobiologic processes th...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1998-06, Vol.90 (12), p.889-905
Main Authors: Dougherty, Thomas J., Gomer, Charles J., Jori, Giulio, Kessel, David, Korbelik, Mladen, Moan, Johan, Peng, Qian
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cancer
Clinical trials
Clinical Trials as Topic
Dihematoporphyrin Ether - therapeutic use
Humans
Inflammation
Light
Medical sciences
Neoplasms - drug therapy
Neoplasms - immunology
Photochemotherapy
Photoradiation therapy and photosensitizing agent
Photosensitizing Agents - therapeutic use
Therapy
Treatment with physical agents
Treatment. General aspects
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Photodynamic therapy involves administration of a tumorlocalizing photosensitizing agent, which may require metabolic synthesis (i.e., a prodrug), followed by activation of the agent by light of a specific wavelength. This therapy results in a sequence of photochemical and photobiologic processes that cause irreversible photodamage to tumor tissues. Results from preclinical and clinical studies conducted worldwide over a 25-year period have established photodynamic therapy as a useful treatment approach for some cancers. Since 1993, regulatory approval for photodynamic therapy involving use of a partially purified, commercially available hematoporphyrin derivative compound (Photofrin®) in patients with early and advanced stage cancer of the lung, digestive tract, and genitourinary tract has been obtained in Canada, The Netherlands, France, Germany, Japan, and the United States. We have attempted to conduct and present a comprehensive review of this rapidly expanding field. Mechanisms of subcellular and tumor localization of photosensitizing agents, as well as of molecular, cellular, and tumor responses associated with photodynamic therapy, are discussed. Technical issues regarding light dosimetry are also considered. [J Natl Cancer Inst 1998;90:889-905]
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/90.12.889